Open AccessMecillinam against genitalChlamydia trachomatisinfection: a small-scale proof-of-concept study shows a low cure rate: Table 1.
Author(s) -
Einar Nilsen,
Marie Aasterød,
Per Sandved Hustad,
Anne O. Olsen
Publication year - 2016
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkw134
Subject(s) - medicine , chlamydia trachomatis , mecillinam , chlamydia , asymptomatic , urine , gynecology , immunology , biology , biochemistry , escherichia coli , enterobacteriaceae , gene
Mecillinam is highly active in vitro against Chlamydia spp. We aimed to determine whether mecillinam should be evaluated further as treatment for genital Chlamydia trachomatis infection.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom